Quoin Pharmaceuticals Key Executives
This section highlights Quoin Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Quoin Pharmaceuticals
(Showing 0 of )
Quoin Pharmaceuticals Earnings
This section highlights Quoin Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2023 | 2024-03-14 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-11-09 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-07 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-12 | N/A | N/A |
Financial Statements
Access annual & quarterly financial statements for Quoin Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $103.44K | $103.64K | $104.11K | $104.77K |
| Gross Profit | $- | $-103.44K | $-103.64K | $-104.11K | $-104.77K |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $3.60B | $3.31M | $2.67M | $1.56M | $244.16K |
| General and Administrative Expenses | $5.93B | $6.07M | $6.58M | $4.50M | $1.43M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.93B | $6.07M | $6.58M | $4.50M | $1.43M |
| Other Expenses | $- | $- | $417.31K | $-14.03M | $-378.33K |
| Operating Expenses | $9.53B | $9.38M | $9.26M | $6.06M | $1.67M |
| Cost and Expenses | $- | $9.38M | $9.26M | $6.06M | $1.67M |
| Interest Income | $- | $692.82K | $95.75K | $1.37K | $47 |
| Interest Expense | $- | $- | $714.08K | $1.09M | $47.02K |
| Depreciation and Amortization | $- | $103.44K | $103.64K | $104.11K | $104.77K |
| EBITDA | $- | $-9.27M | $-8.74M | $-21.37M | $-2.01M |
| EBITDA Ratio | 0.00% | - | - | - | - |
| Operating Income | $- | $-9.38M | $-8.85M | $-20.37M | $-2.05M |
| Operating Income Ratio | 0.00% | - | - | - | - |
| Total Other Income Expenses Net | $- | $714.32K | $-123.79K | $-1.09M | $-425.35K |
| Income Before Tax | $-8.96B | $-8.66M | $-9.38M | $-21.46M | $-2.10M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $- | $22.38K | $-104.04K | $-12.94M | $-331.31K |
| Net Income | $-8.96B | $-8.69M | $-9.28M | $-8.52M | $-1.76M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-1911.50 | $-9.64 | $-22.97 | $-322.49 | $-88.10 |
| EPS Diluted | $-1911.50 | $-9.64 | $-22.97 | $-322.49 | $-88.10 |
| Weighted Average Shares Outstanding | 4.69M | 900.92K | 403.88K | 26.41K | 20.02K |
| Weighted Average Shares Outstanding Diluted | 4.69M | 901.10K | 403.88K | 26.41K | 20.02K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $154.77K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $24.91K | $25.28K | $25.95K | $25.91K | $25.70K | $25.77K | $25.94K | $25.80K | $25.70K | $26.07K | $26.13K | $- | $58.24K | $25.74K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-24.91K | $-25.28K | $128.82K | $-25.91K | $-25.70K | $-25.77K | $-25.94K | $-25.80K | $-25.70K | $-26.07K | $-26.13K | $- | $-58.24K | $-25.74K | $- | $- | $- | $- |
| Gross Profit Ratio | - | 0.00% | - | - | 83.23% | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $1.07M | $1.17M | $492.55K | $826.90K | $815.46K | $758.76K | $625.10K | $1.09M | $613.07K | $745.51K | $726.69K | $587.57K | $1.01M | $260.00K | $239.28K | $56.79K | $116.23K | $26.01K | $26.01K | $75.90K |
| General and Administrative Expenses | $1.33M | $1.36M | $1.62M | $1.62M | $1.39M | $1.37M | $1.63M | $1.68M | $1.47M | $1.58M | $1.94M | $1.59M | $1.97M | $1.04M | $737.61K | $744.97K | $476.71K | $302.12K | $324.19K | $322.83K |
| Selling and Marketing Expenses | $- | $- | $-5.90K | $17.92K | $15.01K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.33M | $1.36M | $1.61M | $1.63M | $1.40M | $1.37M | $1.63M | $1.68M | $1.47M | $1.58M | $1.94M | $1.59M | $1.97M | $1.04M | $737.61K | $744.97K | $476.71K | $302.12K | $324.19K | $322.83K |
| Other Expenses | $- | $- | $- | $- | $14.04K | $- | $-34.47K | $20.43K | $4.36K | $-3.05K | $- | $77.24K | $-8.26M | $146.81K | $-2.97M | $-500.00K | $- | $- | $- | $- |
| Operating Expenses | $2.41M | $2.53M | $2.10M | $2.46M | $2.22M | $2.13M | $2.26M | $2.78M | $2.09M | $2.33M | $2.67M | $2.18M | $2.98M | $1.30M | $976.89K | $801.76K | $592.95K | $328.13K | $350.20K | $398.74K |
| Cost and Expenses | $2.41M | $2.53M | $2.13M | $2.49M | $2.24M | $2.13M | $2.26M | $2.78M | $2.09M | $2.33M | $2.67M | $2.18M | $2.98M | $1.30M | $976.89K | $801.76K | $592.95K | $328.13K | $350.20K | $398.74K |
| Interest Income | $109.33K | $146.39K | $165.26K | $137.51K | $160.26K | $196.43K | $187.59K | $152.05K | $80.61K | $15.13K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $218.92K | $- | $- | $- | $- | $714.08K | $- | $- | $574.13K | $248.16K | $202.51K | $65.60K | $47.02K | $- | $- | $- |
| Depreciation and Amortization | $25.00K | $25.00K | $24.91K | $25.28K | $25.95K | $25.91K | $25.70K | $25.77K | $25.94K | $25.80K | $25.70K | $26.07K | $26.13K | $26.01K | $58.24K | $25.74K | $26.01K | $26.01K | $26.01K | $26.01K |
| EBITDA | $-2.38M | $-2.50M | $-2.11M | $-2.43M | $-2.05M | $-1.89M | $-2.23M | $-2.75M | $-1.97M | $-2.29M | $-2.64M | $-2.15M | $-11.85M | $-1.28M | $-1.58M | $-3.77M | $-566.93K | $-302.12K | $-324.19K | $-372.73K |
| EBITDA Ratio | - | - | - | - | -1322.02% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $- | $-2.35M | $-2.13M | $-2.49M | $-2.24M | $-1.93M | $-2.11M | $-2.82M | $-2.03M | $-2.32M | $-2.67M | $-2.18M | $2.61M | $-1.30M | $-976.89K | $-1.39M | $-971.28K | $-328.13K | $-350.20K | $-398.74K |
| Operating Income Ratio | - | - | - | - | -1448.37% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $-2.31M | $- | $163.09K | $131.00K | $167.79K | $198.54K | $153.12K | $172.48K | $84.97K | $-714.08K | $- | $493.24K | $-8.84M | $-101.36K | $-3.36M | $-2.51M | $-425.35K | $- | $- | $- |
| Income Before Tax | $-2.31M | $-2.35M | $-1.97M | $-2.35M | $-2.07M | $-1.93M | $-2.11M | $-2.60M | $-2.00M | $-3.03M | $-2.67M | $-1.68M | $-11.82M | $-1.40M | $-4.34M | $-3.90M | $-1.02M | $-328.13K | $-350.20K | $-398.74K |
| Income Before Tax Ratio | - | - | - | - | -1338.79% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $1.97M | $2 | $2.07M | $-23.89K | $-187.59K | $-218.92K | $-26.01K | $714.08K | $3 | $-493.24K | $-7.69M | $394.97K | $-2.77M | $-434.40K | $- | $- | $-26.01K | $- |
| Net Income | $-2.31M | $-2.35M | $-1.97M | $-2.35M | $-2.07M | $-1.93M | $-2.11M | $-2.38M | $-1.97M | $-3.74M | $-2.67M | $-1.19M | $-21.46B | $-1.40M | $-4.34M | $-3.90M | $-1.02M | $-328.13K | $-350.20K | $-398.74K |
| Net Income Ratio | - | - | - | - | -1338.79% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-12.25 | $-0.47 | $-0.39 | $-1.12 | $-2.10 | $-1.95 | $-2.13 | $-2.42 | $-4.89 | $-13.64 | $-9.72 | $-21.28 | $-476811.52 | $-70.21 | $-216.88 | $-195.19 | $-12.73 | $-16.41 | $-17.51 | $-33.87 |
| EPS Diluted | $-12.25 | $-0.47 | $-0.39 | $-1.12 | $-2.10 | $-1.95 | $-2.13 | $-2.42 | $-4.89 | $-13.64 | $-9.72 | $-21.27 | $-474659.72 | $-70.11 | $-216.57 | $-194.92 | $-12.72 | $-16.41 | $-17.51 | $-33.87 |
| Weighted Average Shares Outstanding | 186.51K | 5.00M | 5.05M | 2.10M | 987.22K | 987.22K | 987.22K | 987.22K | 403.88K | 274.37K | 274.37K | 55.91K | 45.00K | 20.00K | 20.00K | 20.00K | 80.00K | 20.00K | 20.00K | 11.77K |
| Weighted Average Shares Outstanding Diluted | 186.51K | 5.00M | 5.05M | 2.10M | 987.22K | 987.22K | 987.22K | 987.22K | 403.88K | 274.37K | 274.37K | 55.92K | 45.20K | 20.03K | 20.03K | 20.03K | 80.06K | 20.00K | 20.00K | 11.77K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.62B | $2.40M | $2.86M | $7.48M | $323.83K |
| Short Term Investments | $10.43M | $8.29M | $9.99M | $- | $- |
| Cash and Short Term Investments | $3.62B | $10.69M | $12.85M | $7.48M | $323.83K |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $11.30B | $623.62K | $516.58K | $715.47K | $141.34K |
| Total Current Assets | $14.93B | $11.29M | $13.37M | $8.50M | $465.17K |
| Property Plant Equipment Net | $- | $- | $- | $- | $1.94M |
| Goodwill | $482.85M | $- | $- | $- | $- |
| Intangible Assets | $483.33K | $583.33K | $704.56K | $808.60K | $912.65K |
| Goodwill and Intangible Assets | $483.33M | $583.33K | $704.56K | $808.60K | $912.65K |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $300.00M | $300.00K | $383.39K | $50.00K | $-1.94M |
| Total Non-Current Assets | $783.33M | $883.33K | $1.09M | $858.60K | $912.65K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $15.71B | $12.17M | $14.46M | $9.36M | $1.38M |
| Account Payables | $905.70K | $526.52K | $605.60K | $923.24K | $- |
| Short Term Debt | $- | $- | $- | $743.84M | $1.21M |
| Tax Payables | $77.73K | $93.99K | $159.59K | $199.58K | $148.90K |
| Deferred Revenue | $- | $- | $-600 | $-743.84M | $- |
| Other Current Liabilities | $4.18B | $2.96M | $2.76M | $-740.39M | $6.62M |
| Total Current Liabilities | $4.18B | $3.58M | $3.53M | $8.70M | $7.99M |
| Long Term Debt | $- | $- | $- | $4.12M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $2.32B | $2.92M | $3.52M | $7.03B | $- |
| Total Non-Current Liabilities | $2.32B | $2.92M | $3.52M | $7.03B | $- |
| Other Liabilities | $- | $- | $- | $-7.03B | $- |
| Total Liabilities | $6.50B | $6.51M | $7.05M | $8.70M | $7.99M |
| Preferred Stock | $- | $- | $2.93B | $- | $- |
| Common Stock | $- | $- | $- | $- | $- |
| Retained Earnings | $-55.17B | $-46.20M | $-37.52M | $-28.07M | $-6.61M |
| Accumulated Other Comprehensive Income Loss | $- | $-0 | $-0 | $0 | $5.14M |
| Other Total Stockholders Equity | $64.37B | $51.87M | $44.92M | $28.73M | $100 |
| Total Stockholders Equity | $9.20B | $5.66M | $7.41M | $657.03K | $-6.61M |
| Total Equity | $9.20B | $5.66M | $7.41M | $657.03K | $-6.61M |
| Total Liabilities and Stockholders Equity | $15.71B | $12.17M | $14.46M | $9.36M | $1.38M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $15.71B | $12.17M | $14.46M | $9.36M | $1.38M |
| Total Investments | $10.43M | $8.29M | $9.99M | $- | $- |
| Total Debt | $- | $3.52K | $4.12K | $743.84M | $1.21M |
| Net Debt | $-3.62B | $-2.40M | $-2.86M | $736.36M | $889.48K |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.62B | $3.12M | $2.85M | $1.83M | $2.40M | $3.16M | $4.76M | $3.37M | $2.86M | $5.25M | $2.69M | $5.19M | $7.48M | $652.79K | $1.72M | $1.08M | $323.83K | $- | $18.11M | $13.73M |
| Short Term Investments | $10.43M | $7.19M | $9.73M | $12.86M | $8.29M | $10.82M | $10.68M | $13.62M | $9.99M | $9.91M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $3.62B | $10.31M | $12.57M | $14.69M | $10.69M | $13.98M | $15.44M | $16.99M | $12.85M | $15.16M | $2.69M | $5.19M | $7.48M | $652.79K | $1.72M | $1.08M | $323.83K | $- | $18.11M | $13.73M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $77.30K | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-350.16K | $- | $- | $- | $- | $- |
| Other Current Assets | $11.30B | $190.54K | $11.03M | $574.90K | $591.03K | $159.85K | $234.23K | $398.91K | $516.58K | $496.69K | $826.80K | $809.47K | $715.47K | $305.92K | $301.66K | $48.51K | $141.34K | $- | $58.48K | $- |
| Total Current Assets | $14.93B | $10.50M | $13.22M | $15.26M | $11.29M | $14.14M | $15.67M | $17.39M | $13.37M | $15.66M | $3.51M | $6.00M | $8.50M | $958.71K | $2.02M | $1.13M | $465.17K | $- | $18.11M | $13.73M |
| Property Plant Equipment Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $475.68K | $- | $1.94M | $- | $2.32M | $1.34M |
| Goodwill | $482.85M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $483.33K | $508.33K | $533.33K | $558.33K | $583.33K | $626.53K | $652.54K | $678.55K | $704.56K | $730.57K | $756.58K | $782.59K | $808.60K | $834.62K | $860.63K | $886.64K | $912.65K | $- | $- | $- |
| Goodwill and Intangible Assets | $483.33M | $508.33K | $533.33K | $558.33K | $583.33K | $626.53K | $652.54K | $678.55K | $704.56K | $730.57K | $756.58K | $782.59K | $808.60K | $834.62K | $860.63K | $886.64K | $912.65K | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $114.16K | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-589.84K | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $300.00M | $383.39K | $300.00K | $300.00K | $300.00K | $300.00K | $383.39K | $383.39K | $383.39K | $50.00K | $50.00K | $50.00K | $50.00K | $50.00K | $50.00K | $245.66K | $-1.94M | $- | $- | $- |
| Total Non-Current Assets | $783.33M | $891.72K | $833.34K | $858.34K | $883.34K | $926.53K | $1.04M | $1.06M | $1.09M | $780.57K | $806.58K | $832.59K | $858.60K | $884.62K | $910.63K | $1.13M | $912.65K | $- | $2.32M | $1.34M |
| Other Assets | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $891.00K | $15.29M |
| Total Assets | $15.71B | $11.39M | $14.05M | $16.12M | $12.17M | $15.07M | $16.71M | $18.45M | $14.46M | $16.44M | $4.32M | $6.83M | $9.36M | $1.84M | $2.93M | $2.26M | $1.38M | $- | $21.32M | $30.37M |
| Account Payables | $905.70K | $222.64K | $819.67K | $358.51K | $526.52K | $239.98K | $707.93K | $281.09K | $605.60K | $280.70K | $768.67K | $214.68K | $923.24K | $517.79K | $403.81K | $234.87K | $- | $- | $- | $- |
| Short Term Debt | $- | $- | $- | $600.00K | $- | $- | $- | $- | $- | $- | $- | $600.00K | $743.84M | $6.21M | $6.21M | $3.21M | $1.21M | $- | $396.00K | $- |
| Tax Payables | $77.73K | $79.95K | $90.78K | $77.11K | $93.99K | $165.61K | $199.41K | $153.55K | $159.59K | $153.55K | $153.55K | $168.07K | $199.58K | $168.24K | $165.23K | $- | $148.90K | $- | $- | $- |
| Deferred Revenue | $- | $- | $-600.00K | $-600.00K | $-600 | $-600 | $-725 | $-650 | $-600 | $-600 | $-600 | $-600.00K | $-736.44M | $6.80M | $165.23K | $1 | $- | $- | $- | $- |
| Other Current Liabilities | $4.18B | $3.17M | $3.04M | $3.19M | $2.96M | $4.17M | $3.51M | $3.73M | $2.76M | $3.16M | $2.74M | $2.60M | $-740.39M | $6.67M | $6.33M | $6.87M | $6.62M | $- | $- | $- |
| Total Current Liabilities | $4.18B | $3.47M | $3.95M | $4.22M | $3.58M | $4.58M | $4.41M | $4.16M | $3.53M | $3.60M | $3.67M | $3.59M | $8.70M | $13.57M | $13.11M | $10.32M | $7.99M | $- | $396.00K | $- |
| Long Term Debt | $- | $- | $2.62M | $2.77M | $- | $- | $- | $- | $- | $- | $- | $3.97M | $4.12M | $- | $61.99K | $2.45M | $- | $- | $196.00K | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $2.32B | $2.47M | $- | $19 | $2.92M | $3.07M | $3.22M | $3.37M | $3.52M | $3.67M | $3.82M | $- | $7.03B | $4.52M | $4.61M | $- | $- | $- | $-196.00K | $- |
| Total Non-Current Liabilities | $2.32B | $2.47M | $2.62M | $2.77M | $2.92M | $3.07M | $3.22M | $3.37M | $3.52M | $3.67M | $3.82M | $3.97M | $7.03B | $4.52M | $4.67M | $2.45M | $- | $- | $- | $- |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $0 | $- | $- | $-0 | $- | $-7.03B | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $6.50B | $5.95M | $6.58M | $7.00M | $6.51M | $7.65M | $7.64M | $7.54M | $7.05M | $7.27M | $7.49M | $7.56M | $8.70M | $18.10M | $17.78M | $12.77M | $7.99M | $- | $396.00K | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $2.93M | $2.93M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2 | $- | $- | $- | $100 | $100 | $100 | $- | $- | $- | $- |
| Retained Earnings | $-55.17B | $-52.85M | $-50.50M | $-48.53M | $-46.20M | $-44.15M | $-42.23M | $-40.12M | $-37.52M | $-35.52M | $-32.42M | $-29.75M | $-28.07M | $-16.25M | $-14.85M | $-10.51M | $-6.61M | $- | $-100.86M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-0 | $-0 | $-0 | $-0 | $-0 | $-0 | $-0 | $-0 | $0 | $0 | $- | $5.20M | $- | $- | $-4.51M | $- | $- |
| Other Total Stockholders Equity | $64.37B | $58.30M | $57.98M | $57.66M | $51.87M | $51.57M | $51.30M | $51.03M | $44.92M | $44.68M | $29.25M | $29.02M | $28.73M | $- | $- | $- | $100 | $29.23M | $105.16M | $41.35M |
| Total Stockholders Equity | $9.20B | $5.44M | $7.48M | $9.13M | $5.66M | $7.41M | $9.07M | $10.91M | $7.41M | $9.17M | $-3.17M | $-729.41K | $657.03K | $-16.25M | $-14.85M | $-10.51M | $-6.61M | $-4.51M | $- | $18.85M |
| Total Equity | $9.20B | $5.44M | $7.48M | $9.13M | $5.66M | $7.41M | $9.07M | $10.91M | $7.41M | $9.17M | $-3.17M | $-729.41K | $657.03K | $-16.25M | $-14.85M | $-10.51M | $-6.61M | $-4.51M | $- | $18.85M |
| Total Liabilities and Stockholders Equity | $15.71B | $11.39M | $14.05M | $16.12M | $12.17M | $15.07M | $16.71M | $18.45M | $14.46M | $16.44M | $4.32M | $6.83M | $9.36M | $1.84M | $2.93M | $2.26M | $1.38M | $-4.51M | $21.32M | $30.37M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $15.71B | $11.39M | $14.05M | $16.12M | $12.17M | $15.07M | $16.71M | $18.45M | $14.46M | $16.44M | $4.32M | $6.83M | $9.36M | $1.84M | $2.93M | $2.26M | $1.38M | $-4.51M | $21.32M | $30.37M |
| Total Investments | $10.43M | $7.19M | $9.73M | $12.86M | $8.29M | $10.82M | $10.68M | $13.62M | $9.99M | $9.91M | $- | $- | $- | $- | $114.16K | $- | $- | $- | $- | $- |
| Total Debt | $- | $- | $3.22M | $3.37M | $3.52K | $3.67K | $3.95K | $4.02K | $4.12K | $4.27K | $4.42K | $4.57M | $743.84M | $6.21M | $6.21M | $5.66M | $1.21M | $- | $396.00K | $- |
| Net Debt | $-3.62B | $-3.12M | $378.60K | $1.54M | $-2.40M | $-3.16M | $-4.76M | $-3.37M | $-2.86M | $-5.25M | $-2.68M | $-615.48K | $736.36M | $5.56M | $4.49M | $4.58M | $889.48K | $- | $-17.71M | $-13.73M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-8.96B | $-8.69M | $-9.38M | $-21.46M | $-2.10M |
| Depreciation and Amortization | $100.00M | $103.71K | $104.04K | $104.04K | $104.04K |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.26B | $1.09M | $764.01K | $- | $- |
| Change in Working Capital | $-2.14K | $95.20K | $-94.35K | $1.33M | $274.36K |
| Accounts Receivables | $- | $- | $- | $- | $60.19K |
| Inventory | $- | $- | $- | $- | $-60.19K |
| Accounts Payables | $275.95K | $53.78K | $-217.81K | $1.35M | $227.31K |
| Other Working Capital | $-278.09K | $41.42K | $123.45K | $-18.68K | $47.04K |
| Other Non Cash Items | $-253.72M | $-471.31K | $127.06K | $14.31M | $378.33K |
| Net Cash Provided by Operating Activities | $-7.86B | $-7.86M | $-8.48M | $-5.72M | $-1.34M |
| Investments in Property Plant and Equipment | $- | $- | $-250.00K | $-625.00K | $-125.00K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $-17.25B | $-18.04M | $-9.90M | $- | $- |
| Sales Maturities of Investments | $26.93B | $20.23M | $14.88B | $- | $- |
| Other Investing Activities | $-11.57B | $5.64K | $-14.88B | $-625 | $-125 |
| Net Cash Used for Investing Activities | $-1.89B | $2.19M | $-10.15M | $-625.00K | $-125.00K |
| Debt Repayment | $- | $- | $-311.67K | $3.48M | $909.98K |
| Common Stock Issued | $- | $5.83M | $14.82M | $10.11M | $-142.33K |
| Common Stock Repurchased | $- | $- | $-14.82M | $- | $- |
| Dividends Paid | $- | $- | $-65.27M | $- | $- |
| Other Financing Activities | $10.97B | $5.22M | $14.32M | $10.03M | $877.49K |
| Net Cash Used Provided by Financing Activities | $10.97B | $5.22M | $14.01M | $13.50M | $1.79M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-5.24M |
| Net Change in Cash | $1.22B | $-459.43K | $-4.62M | $7.16M | $-4.92M |
| Cash at End of Period | $3.62B | $2.40M | $2.86M | $7.48M | $323.83K |
| Cash at Beginning of Period | $2.40M | $2.86M | $7.48M | $323.83K | $5.24M |
| Operating Cash Flow | $-7.86B | $-7.86M | $-8.48M | $-5.72M | $-1.34M |
| Capital Expenditure | $- | $- | $-250.00K | $-625.00K | $-125.00K |
| Free Cash Flow | $-7.86B | $-7.86M | $-8.73M | $-6.35M | $-1.46M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-8.96B | $-2.33M | $-1.97M | $-2.35M | $-2.07M | $-1.93M | $-2.11M | $-2.60M | $-2.00M | $-3.03M | $-2.67M | $-1.68M | $-11.82M | $-1.40M | $-4.34M | $-3.90M | $-1.02M | $-328.13K | $-350.20K | $-398.74K |
| Depreciation and Amortization | $99.92M | $25.00K | $24.91K | $25.28K | $25.95K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K | $26.01K |
| Deferred Income Tax | $- | $- | $- | $- | $-1.34M | $- | $- | $- | $- | $- | $-229 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.26B | $313.12K | $313.12K | $306.31K | $300.20K | $268.50K | $264.38K | $261.47K | $267.28K | $267.28K | $229.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $-211.50K | $-312.66K | $-353.25K | $665.91K | $-1.38M | $449.35K | $340.97K | $702.67K | $-464.65K | $52.48K | $261.35K | $56.47K | $350.73K | $617.40K | $-66.62K | $427.62K | $70.84K | $49.01K | $- | $- |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $-480.30K | $-277.05K | $649.60K | $-986.03K | $286.21K | $174.09K | $584.99K | $-69.31K | $-589.31K | $278.68K | $162.13K | $885.68K | $320.72K | $-269.14K | $410.53K | $23.80K | $49.01K | $- | $- |
| Other Working Capital | $-211.50K | $167.64K | $-76.21K | $16.31K | $-393.25K | $163.14K | $166.88K | $-584.99K | $-395.33K | $641.79K | $-17.34K | $-105.66K | $-534.95K | $296.68K | $202.51K | $17.09K | $47.04K | $- | $- | $- |
| Other Non Cash Items | $-253.54M | $140.29K | $617.05K | $-387.42K | $1.20M | $-138.71K | $-97.13K | $-133.62K | $229.97K | $390.33K | $229.44K | $-493.24K | $8.26M | $-146.81K | $3.16M | $3.04M | $378.33K | $49.01K | $104.61K | $49.89K |
| Net Cash Provided by Operating Activities | $-7.85B | $-2.17M | $-2.00M | $-1.45M | $-3.26M | $-1.32M | $-1.57M | $-1.75M | $-1.94M | $-2.29M | $-2.15M | $-2.09M | $-3.18M | $-907.54K | $-1.22M | $-413.73K | $-543.12K | $-253.11K | $-219.57K | $-322.83K |
| Investments in Property Plant and Equipment | $- | $-0 | $0 | $- | $- | $- | $- | $- | $250.00K | $1.64K | $-200.00K | $-50.00K | $-250.00K | $-107.50K | $-125.00K | $-142.50K | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-17.24B | $-1.57M | $68.39K | $-9.76M | $-177.68K | $-4.60M | $9.80K | $-13.49M | $-66.76K | $-9.79M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $26.92B | $9.67M | $3.13M | $5.24M | $2.81M | $4.60M | $3.04M | $10.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-11.56B | $-5.50M | $3.15M | $-4.47M | $2.64K | $1 | $-9.80K | $-3.49K | $-10.14B | $-107.13K | $-200 | $-50.00K | $-250.00K | $-107.50K | $141.02K | $-141.02K | $-125.00K | $- | $- | $- |
| Net Cash Used for Investing Activities | $-1.89B | $2.60M | $3.20M | $-4.52M | $2.63M | $821 | $3.04M | $-3.49M | $-10.14B | $-9.90M | $-200.00K | $-50.00K | $-250.00K | $-107.50K | $-125.00K | $-142.50K | $-125.00K | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.06M | $1.41M | $909.98K | $- | $- | $- |
| Common Stock Issued | $- | $-5.52M | $-25.07K | $5.54M | $57.45K | $-13.52K | $-4.25K | $5.79M | $- | $14.75M | $- | $- | $10.27M | $-197.84K | $33.43K | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $-65.27M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $10.96B | $-149.89K | $-136.28K | $5.33M | $-240.03K | $-275.00K | $-75.00K | $5.75M | $-520.25K | $14.75M | $-150.00K | $-150.00K | $10.26M | $-52.77K | $-76.97K | $-100.02K | $81.97K | $253.11K | $219.57K | $322.83K |
| Net Cash Used Provided by Financing Activities | $10.96B | $-149.89K | $-174.61K | $5.39M | $-182.58K | $-275.00K | $-75.00K | $5.75M | $-446.86K | $14.75M | $-150.00K | $-150.00K | $10.26M | $-52.77K | $1.99M | $1.31M | $991.95K | $253.11K | $219.57K | $322.83K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-4.88K | $- | $- | $- | $10.14B | $- | $- | $- | $7.48B | $217 | $-217 | $- | $- | $- | $- | $- |
| Net Change in Cash | $3.62B | $271.62K | $1.01M | $-567.68K | $-762.16K | $-1.60M | $1.39M | $511.23K | $-2.39M | $2.56M | $-2.50M | $-2.29M | $6.83M | $-1.07M | $642.80K | $753.75K | $323.83K | $- | $- | $- |
| Cash at End of Period | $3.62B | $3.12M | $2.85M | $1.83M | $2.40M | $3.16M | $4.76M | $3.37M | $2.86M | $5.25M | $2.69M | $5.19M | $7.48M | $652.79K | $1.72M | $1.08M | $323.83K | $- | $- | $- |
| Cash at Beginning of Period | $3.12M | $2.85M | $1.83M | $2.40M | $3.16M | $4.76M | $3.37M | $2.86M | $5.25M | $2.69M | $5.19M | $7.48M | $652.79K | $1.72M | $1.08M | $323.83K | $- | $- | $- | $- |
| Operating Cash Flow | $-7.85B | $-2.18M | $-2.00M | $-1.45M | $-3.26M | $-1.32M | $-1.57M | $-1.75M | $-1.94M | $-2.29M | $-2.15M | $-2.09M | $-3.18M | $-907.54K | $-1.22M | $-413.73K | $-543.12K | $-253.11K | $-219.57K | $-322.83K |
| Capital Expenditure | $- | $-0 | $0 | $- | $- | $- | $- | $- | $250.00K | $1.64K | $-200.00K | $-50.00K | $-250.00K | $-107.50K | $-125.00K | $-142.50K | $- | $- | $- | $- |
| Free Cash Flow | $-7.85B | $-2.18M | $-2.00M | $-1.45M | $-3.26M | $-1.32M | $-1.57M | $-1.75M | $-1.69M | $-2.29M | $-2.35M | $-2.14M | $-3.43M | $-1.02M | $-1.35M | $-556.23K | $-543.12K | $-253.11K | $-219.57K | $-322.83K |
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
$6.58
Stock Price
$1.68M
Market Cap
3
Employees
Ashburn, VA
Location
Revenue (FY 2024)
$-
0.0% YoY
Net Income (FY 2024)
$-8.96B
-103076.2% YoY
EPS (FY 2024)
$-1911.50
-19728.8% YoY
Free Cash Flow (FY 2024)
$-7.86B
-99809.5% YoY
Profitability
Gross Margin
0.0%
Net Margin
0.0%
ROE
-97.4%
ROA
-57.1%
Valuation
P/E Ratio
0.00
P/S Ratio
0.00
EV/EBITDA
0.00
Market Cap
$1.68M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-7.86B
-99809.5% YoY
Free Cash Flow
$-7.86B
-99809.5% YoY
Balance Sheet Summary
Total Assets
$15.71B
128990.7% YoY
Total Debt
$-
100.0% YoY
Shareholder Equity
$9.20B
31125.9% YoY
Dividend Overview
No Dividend Data
Quoin Pharmaceuticals, Ltd. doesn't currently pay dividends.
Quoin Pharmaceuticals Dividends
Explore Quoin Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Quoin Pharmaceuticals News
Read the latest news about Quoin Pharmaceuticals, including recent articles, headlines, and updates.
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company's NETHERTON NOW website ASHBURN, Va., April 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
ASHBURN, Va., April 02, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application of QRX003, the subject's skin remains almost completely healed demonstrating the durability of ongoing daily treatment with the product. In addition, the patient has continued to have no requirement for previously necessary medications such as antibiotics, antivirals, antihistamines and glucocorticoids. Importantly, with the patient's pruritus or itch almost completely eliminated, she continues to experience zero nightly sleep disturbances without the need for any sedating medication, marking the first continuous period of uninterrupted sleep in the patient's life. No adverse events have been reported to date after 6 weeks of whole body treatment with QRX003.
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
ASHBURN, Va., March 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late-stage clinical, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announced it has filed a U.S. patent application for novel topical formulations to treat a number of skin diseases, including Netherton Syndrome (NS). Quoin's lead product, QRX003, is currently being tested in four Netherton Syndrome clinical trials. Three of these trials are being conducted under Quoin's open Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). QRX003 is also currently being tested in a pediatric NS patient at the Children's Hospital in Dublin, Ireland and the Company intends to expand this study to include additional children with NS in Spain, the United Kingdom and potentially other countries. The Company has recently reported positive initial clinical data from the two open label studies for which data is available. This patent application also includes Peeling Skin Syndrome for which Quoin has an ongoing Investigator Clinical Study in a pediatric patient in New Zealand. There are currently no FDA approved treatments for either Netherton Syndrome or Peeling Skin Syndrome.
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 progress.
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
ASHBURN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced it has filed U.S. and International patent applications for novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare diseases including microcystic lymphatic malformations, venous malformations and angiofibromas. The products are being developed using Quoin's in-licensed proprietary Invisicare delivery technology. There are currently no FDA approved treatments for either microcystic lymphatic malformations or venous malformations.
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study
ASHBURN, Va., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. Dramatic improvement was observed in the patient's disease state with clear visual evidence of skin healing observed after just two weeks of whole-body application of QRX003. No adverse events have been reported to date.
Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure
ASHBURN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has launched the “NETHERTON NOW” campaign to shed light on the profound and poorly understood impacts of Netherton Syndrome, a devastating genetic disease that has been significantly misdiagnosed in the past. It is estimated that up to 20% of babies born with Netherton Syndrome do not survive, highlighting the urgent need for greater awareness and new treatment options.
Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
ASHBURN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome.
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment. Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select rare skin diseases and for the right to use its proprietary formula for Netherton Syndrome.
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) CEO Dr. Michael Myers, who shares the company's notable interim data in its ongoing Netherton Syndrome clinical trials.
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
ASHBURN, Va., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces additional positive interim clinical data from one of its ongoing Netherton Syndrome clinical studies.
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its “reasonable best efforts” public offering of 15,111,110 ordinary shares represented by 15,111,110 American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof), Series F warrants to purchase an aggregate of up to 15,111,110 ordinary shares represented by 15,111,110 ADSs and Series G warrants to purchase an aggregate of up to 15,111,110 ordinary shares represented by 15,111,110 ADSs at a combined purchase price of $0.45 per ADS and associated Series F and Series G warrants. The Series F warrants and Series G warrants will have an exercise price of $0.45 per share, will be exercisable immediately following the date of issuance and will expire in two years and five years, respectively, from their issuance.
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
ASHBURN, Va., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces FDA clearance to initiate a new additional Netherton Syndrome (NS) clinical study for QRX003. QRX003 is a topical lotion that contains a broad-spectrum serine protease inhibitor designed to target the kallikreins in the skin responsible for the excessive skin shedding associated with this disease.
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
ASHBURN, Va., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive interim clinical data from two of its ongoing Netherton Syndrome clinical studies.
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company's American Depositary Shares (ADSs), signaling their confidence in the company's growth and direction.
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announced Plans to Initiate Clinical Study in Peeling Skin Syndrome Continues to Evaluate M&A Opportunities in Rare and Orphan Diseases ASHBURN, Va., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening additional clinical sites in other countries ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024.
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024.
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2025 ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?
Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is falling on Tuesday after the clinical-stage specialty pharmaceutical company announced details of a public offering for its shares. The public offering has Quoin Pharmaceuticals selling 4,062,500 shares of QNRX stock for $1.60 each.
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX). The trials focus on the innovative formulation "QRX003," powered by Skinvisible's Invisicare® proprietary drug delivery technology, to address the challenges of Netherton Syndrome ("NS").
PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan
NEW YORK, NY, December 13, 2023 – Quoin Pharmaceuticals (Nasdaq:QNRX) has received U.S. Food and Drug Administration (FDA) clearance to implement several protocol amendments to its two ongoing clinical trials for QRX003, which is a potential treatment for Netherton Syndrome, a rare genetic skin disease for which there is no cure and no approved treatments.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for QNRX.